Clinical Trials

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy


Study ID
Astellas 2215-CL-0201

NCT Number
NCT02752035 (Click on the NCT number for more information about the trial)

Research Study Number
2016-0274

Principle Investigator
Dr. James McCloskey

Phase
II

Sponsor
Astellas


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now